Marta Ramírez-Calvo
YOU?
Author Swipe
View article: Supplementary Table S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S1. Univariate analysis of cell densities.
View article: Supplementary Figure S5 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S5 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S5. CXCL10 protein expression in cell culture supernatant. The expression levels of CXCL10 soluble protein were measured after anti-CD3/CD28 stimulation and anti-PD-1 treatment in PBMC cultures (A) and tumor multi-cult…
View article: Supplementary Table S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S4. MAXSTAT cut-off calculated for the Δ of gene expression between week 13 and baseline samples.
View article: Data from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Data from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Purpose:The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial.Experi…
View article: Supplementary Figure S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S4. Correlation between progression-free survival (PFS) and the dynamic alteration in the expression of additional soluble proteins in plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). PF…
View article: Supplementary Figure S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S3. Dynamic modulation of soluble factors in paired plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). Significance was defined as p<0.05 and calculated by Wilcoxon paired test. Concentrat…
View article: Supplementary Figure S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S2. Correlation between progression-free survival (PFS) and the dynamic increase in cytologic markers. A) CD3; B) CD4; C) CD8; D) CD20; E) CD66b; F) CD68 and G) CD138. PFS cut-off was defined as 9.4 months and calculat…
View article: Supplementary Table S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S3. Univariate analysis of the dynamic (Δ) alteration in the expression levels of genes modulated by treatment.
View article: Supplementary Table S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S2. Dynamic gene expression between baseline and week 13.
View article: Supplementary Figure S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S1. Consort diagram. Number of samples included in the correlative studies of HTG transcriptomics, multiplexed immunoassays and multiplexed immune-phenotyping.
View article: The Impact of Tube Type, Centrifugation Conditions, and Hemolysis on Plasma Circulating MicroRNAs
The Impact of Tube Type, Centrifugation Conditions, and Hemolysis on Plasma Circulating MicroRNAs Open
Background: In recent years, liquid biopsy has emerged as a promising tool for the diagnosis and prognosis of numerous diseases, including cancer. Among the biomolecules analyzed in liquid biopsies are plasma circulating microRNAs (miRNAs)…
View article: The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study Open
Genomic Instability (GI) is a transversal phenomenon shared by several tumor types that provide both prognostic and predictive information. In the context of high-grade serous ovarian cancer (HGSOC), response to DNA-damaging agents such as…
View article: Isolation and characterization of urine microvesicles from prostate cancer patients: different approaches, different visions
Isolation and characterization of urine microvesicles from prostate cancer patients: different approaches, different visions Open
Background Because of their specific and biologically relevant cargo, urine extracellular vesicles (EVs) constitute a valuable source of potential non-invasive biomarkers that could support the clinical decision-making to improve the manag…
View article: Isolation and Characterization of Urine Microvesicles from Prostate Cancer Patients: Different Approaches, Different Visions
Isolation and Characterization of Urine Microvesicles from Prostate Cancer Patients: Different Approaches, Different Visions Open
Background Because of their specific and biologically relevant cargo, urine extracellular vesicles (EVs) constitute a valuable source of potential non-invasive biomarkers that could support the clinical decision-making to improve the manag…
View article: Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study
Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study Open
MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore ne…
View article: Additional file 1: of Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
Additional file 1: of Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS) Open
Table S1: POCV HCSs diagnostic criteria. Referral indications for cancer predisposition assessment. (ZIP 67 kb)